ANI Pharmaceuticals Inc

BSFA

Company Profile

  • Business description

    ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

  • Contact

    210 Main Street West
    BaudetteMN56623
    USA

    T: +1 218 634-3500

    E: [email protected]

    https://www.anipharmaceuticals.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2025

    Employees

    897

Stocks News & Analysis

stocks

Have the 3 biggest losers of the ASX 200 fallen too far?

Finding value in some of the ASX’s worst recent performers.
stocks

Rethinking the way we invest in Aussie tech

Investing in Tech companies has many caveats from traditional investing. Let’s dive into how you can gauge the true profitability of a tech company.
stocks

Undervalued ASX listed payment provider

Strong start to the new fiscal year.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,884.7038.30-0.43%
CAC 408,122.7123.240.29%
DAX 4023,836.7968.830.29%
Dow JONES (US)47,716.42289.300.61%
FTSE 1009,720.5126.580.27%
HKSE25,967.11108.220.42%
NASDAQ23,365.69151.000.65%
Nikkei 22549,465.73788.18-1.57%
NZX 50 Index13,446.3642.79-0.32%
S&P 5006,849.0936.480.54%
S&P/ASX 2008,585.1029.00-0.34%
SSE Composite Index3,893.785.190.13%

Market Movers